Literature DB >> 19411235

[Rhino-orbito-cerebral mucormycosis in the diabetic: a better known pathology in Tunisia].

S Anane1, E Kaouech, S Belhadj, L Ammari, R Abdelmalek, T Ben Chaabane, S Ben Lakhal, A Cherif, M Ammamou, K Ben Fadhel, K Kallel, E Chaker.   

Abstract

This is a retrospective study including 17 patients with rhino-orbito-cerebral mucormycosis diagnosed in a period of 16 years, between 1992 and 2007, in 8 men and 9 women. All patients were diabetic with ketoacidosis diabetes in 8 cases. Necrosis facial and ophthalmic symptoms were the most frequent presenting manifestations. The diagnosis was confirmed by mycological examination, with or without histopathology, identifying Rhizopus oryzae in 12 cases. Treatment consisted in systemic amphotericin B combined with surgical treatment in only 7 cases. The mortality rate was high (65%) due principally to the delay in diagnosis and absence of surgical treatment.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19411235     DOI: 10.1684/abc.2009.0323

Source DB:  PubMed          Journal:  Ann Biol Clin (Paris)        ISSN: 0003-3898            Impact factor:   0.459


  4 in total

1.  Progressive left-sided facial swelling and proptosis.

Authors:  Ritu Kumar; Naheed A Lakhani; Umesh Narsinghani
Journal:  Can J Infect Dis Med Microbiol       Date:  2015 Mar-Apr       Impact factor: 2.471

2.  Outcome of mucormycosis after treatment: report of five cases.

Authors:  F Bellazreg; Z Hattab; S Meksi; S Mansouri; W Hachfi; N Kaabia; M Ben Said; A Letaief
Journal:  New Microbes New Infect       Date:  2014-12-27

3.  Erratum to, 'Outcome of mucormycosis after treatment: report of five cases'.

Authors:  F Bellazreg; Z Hattab; S Meksi; S Mansouri; W Hachfi; N Kaabia; M Ben Said; A Letaief
Journal:  New Microbes New Infect       Date:  2016-02-27

Review 4.  Update on invasive fungal infections in the Middle Eastern and North African region.

Authors:  Marwan Osman; Aisha Al Bikai; Rayane Rafei; Hassan Mallat; Fouad Dabboussi; Monzer Hamze
Journal:  Braz J Microbiol       Date:  2020-07-05       Impact factor: 2.476

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.